FOR IMMEDIATE RELEASE September 28, 2022 Media Contact: Amanda McGee Director of Marketing & Communications Communication@LissMD.com (706) 327-4000 Eisai Co., Ltd. and Biogen Inc. have announced that Lecanemab has demonstrated a significant reduction of clinical decline in early Alzheimer’s disease. Lecanemab is likely to be the first fully approved disease modifying drug for this dreaded illness. Columbus, Georgia, home to Columbus Memory Center, has less than 200,000 people, but enrolled the third highest number of research subjects for each of Lecanemab’s pivotal trials COLUMBUS, GA. Sept 28, 2022 – Columbus [...]

Columbus Memory Center is rewarded for its proven success and innovative approach to providing inclusive Alzheimer’s care and research. Columbus, GA – Columbus Memory Center has been chosen to receive a $150,000 grant to promote the safeguards, benefits, and honesty of today’s FDA approved Alzheimer’s research trials to Columbus’ minority communities. “Columbus Memory Center already out-performs most of the nation’s Alzheimer’s research centers in both patient recruitment and minority inclusion” according to its Medical Director, Dr. Jonathan Liss.  “For this reason, along with our innovative approaches [...]